• 1
    Hulka BS. Epidemiology of susceptibility to breast cancer. Prog Clin Biol Res. 1996; 395: 159174.
  • 2
    Sainsbury R. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy? Br J Cancer. 2004; 90: 17331739.
  • 3
    Jones KL, Buzdar AU. A review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer. 2004; 11: 391406.
  • 4
    Nolvadex Adjuvant Trial Organisation (NATO). Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet. 1983; 1: 257261.
  • 5
    Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998; 351: 14511467.
  • 6
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 16871717.
  • 7
    Hortobagyi GN, Kau S-W, Buzdar AU, et al. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis [abstract]? J Clin Oncol. 2004; 22( Suppl 14): 585.
  • 8
    Fisher B, Constantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989; 320: 479484.
  • 9
    Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001; 93: 684690.
  • 10
    Clinical Trial Service Unit. Adjuvant tamoxifen: longer against shorter (ATLAS). Protocol. ATLAS Office. Oxford, UK: Clinical Trials Service Unit, Radcliffe Infirmary, April 1995.
  • 11
    Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst. 1996; 88: 18341839.
  • 12
    Baum M, Budzar AU, Cuzick J, et al. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359: 21312139.
  • 13
    Howell A, Cuzick J, Baum M, et al. ATAC Trialists' Group. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365: 6062.
  • 14
    Buzdar AU, on behalf of the ATAC Trialists' group. Impact of adjuvant chemotherapy prior to endocrine therapy: 68 month results from the arimidex, tamoxifen, alone or in combination (ATAC) trial [abstract]. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol. 2005; 23( Suppl 16): 608.
  • 15
    Arimidex package insert. AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, 2004.
  • 16
    Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol. 2004; 22: 42614271.
  • 17
    Thürlimann B. Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer, BIG 1-98: a prospective, randomized, double blind, phase III study [abstract]. Breast. 2004; 14: S3.S4.
  • 18
    Coombes RC, Hall E, Gibson LJ, et al. Intergroup exemestane study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350: 10811092.
  • 19
    Coombes RC, Hall E, Snowdon CF, Bliss JM. The intergroup exemestane study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis [abstract]. Breast Cancer Res Treat. 2004; 88: S7.3.
  • 20
    Jakesz R, Kaufmann M, Gnant M, et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen; combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 trial [abstract]. Breast Cancer Res Treat 2004; 88: S7.2.
  • 21
    Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003; 349: 17931802.
  • 22
    Goss PE, Ingle JN, Martino S, et al. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer [abstract]. J Clin Oncol. 2004; 22( Suppl 14): 847.
  • 23
    Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005; 23: 619629.
  • 24
    Dowsett M, on behalf of the ATAC Trialists Group, Royal Marsden Hospital, London, United Kingdom. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status [abstract]. Presented at the 26th Annual San Antonio Breast Cancer Symposium. December 2003: 4.
  • 25
    Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, crossover study. J Clin Oncol. 2002; 20: 751757.
  • 26
    Bhatnagar AS. Aromatase inhibitors in advanced breast cancer: there are efficacy differences. Br J Cancer. 2005; 92: 11731174; author reply 1175–1176.
  • 27
    Bhatnagar AS, Batzl C, Hausler A, Schieweck K, Lang M, Trunet PF. Pharmacology of nonsteroidal aromatase inhibitors. In: PasqualiniJR, KatzenellenbogenBS, editors. Hormone dependent cancer. New York: Marcel Dekker, 1996: 155168.
  • 28
    Janicke F. Are all aromatase inhibitors the same? A review of the current evidence. Breast. 2004; 13: S10S18.
  • 29
    St. Gallen Conference Authors. Primary therapy of early breast cancer, 9th International Conference. Breast. 2005; 14: S1S56.